COGT catalyst calendar

Cogent Biosciences, Inc.

Upcoming catalysts
4
Cash runway
6.3 months
Cash & investments
$181M
Phase 3 programs
1

Cogent Biosciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 8, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.

Cash runway is approximately 6.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 6 concluded trials, 33% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 8, 2026 est. Next quarterly earnings (projected) Earnings —
March 15, 2027 A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Trial Milestone Phase 1/Phase 2
May 15, 2028 A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors Trial Milestone Phase 1
July 15, 2029 A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors Trial Milestone Phase 1

Track COGT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open COGT in the tracker

Recent history

DateEventTypePhase
September 2, 2026 8-K filed: Material agreement Corporate —
August 10, 2026 Quarterly results filed (8-K) Earnings —
August 10, 2026 8-K filed: Other event Filing —
May 5, 2026 Quarterly results filed (8-K) Earnings —
February 17, 2026 Quarterly results filed (8-K) Earnings —
December 8, 2025 8-K filed: Other event Filing —
November 18, 2025 8-K filed: Material agreement Corporate —
November 13, 2025 8-K filed: Material agreement, Other event Corporate —
November 10, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 3, 2025 Quarterly results filed (8-K) Earnings —
September 30, 2025 (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors Trial Milestone Phase 3
September 19, 2025 (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis Trial Milestone Phase 2
September 11, 2025 8-K filed: Material agreement Corporate —
August 5, 2025 Quarterly results filed (8-K) Earnings —
July 10, 2025 Quarterly results filed (8-K) Earnings —
July 7, 2025 8-K filed: Other event Filing —
June 11, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
June 5, 2025 8-K filed: Reg FD disclosure Filing —
May 22, 2025 (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Trial Milestone Phase 2
May 6, 2025 Quarterly results filed (8-K) Earnings —
September 21, 2020 Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Trial Milestone Phase 1
May 11, 2020 CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors Trial Milestone Phase 1/Phase 2
March 12, 2020 Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers Trial Milestone Phase 1
February 12, 2020 Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Trial Milestone Phase 1
October 1, 2019 Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.